Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY1142524 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BAY1142524 (5 mg) | EXPERIMENTAL | 12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment |
| BAY1142524 (10 mg) | EXPERIMENTAL | 12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment |
| BAY1142524 (25 mg) | EXPERIMENTAL | 12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment |
| BAY1142524 (50 mg) | EXPERIMENTAL | 12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment |
| Name | Type | Description |
|---|---|---|
| BAY1142524 | DRUG | 5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks |
| Placebo | DRUG | The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages. |
Inclusion Criteria: * Clinically stable patients with left-ventricular dysfunction (LVEF ≤ 45%) after myocardial infarction, whereby the MI occurred 6 or more months before randomization. * New York Heart Association (NYHA) class I-II. * Left-ventricular ejection fraction ≤ 45%, confirmed by a...
Top 20 of 31 competitors
BAY1142524 is an investigational small molecule being developed for heart failure. It is a chymase inhibitor studied in clinically stable patients with left-ventricular dysfunction. The drug is in Phase 2 clinical development and is not yet approved by regulatory authorities.
BAY1142524 targets chymase, an enzyme involved in tissue remodeling and fibrosis. By inhibiting chymase, the drug aims to address mechanisms underlying heart failure progression. This target is being investigated for its potential role in cardiovascular disease.
BAY1142524 is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded over-the-counter under the ticker BAYRY. The company is conducting clinical research on this compound for heart failure.
BAY1142524 is in Phase 2 clinical development. It has completed a Phase 2 trial, and the drug remains investigational. It has not received FDA approval and is still being studied for safety and tolerability in patients with left-ventricular dysfunction.
BAY1142524 has one completed clinical trial, NCT02452515, a single-blind, randomized, double-blind, controlled Phase 2 study. The trial enrolled 49 patients with heart failure and left-ventricular dysfunction across Denmark, Germany, and Italy, investigating safety and tolerability.
BAY1142524 is the primary name for this investigational drug. No alternative names have been reported in clinical trial registries. It is identified solely by this compound designation in the completed Phase 2 study.